Dr. Hans Loibner (emeritus CEO)

As the first CEO to run APEIRON, Dr. Hans Loibner had a long and distinguished career at the Company. He retired after 13 successful years as of July 15, 2018 as Chief Executive Officer and continues to support the Company as a senior advisor. Dr. Loibner holds a PhD in Organic Chemistry from the University of Vienna. He has more than 20 years of experience in R&D management at Sandoz/Novartis and had been acting for 18 years as CEO of Biotech companies before joining Apeiron. Since 1985 he has been engaged in clinically oriented cancer immunotherapy.

 

Lukas Kadawy

He served as Chief Financial Officer (CFO) for Apeiron from 2005 until 2015 and is now acting as advisor.
> more

 

Ulrich Granzer, PhD

Ulrich Granzer has a wide range of experience in all aspects of drug development and regulatory affairs, including drug safety and GXP.
> more

 

Ruth Ladenstein, MD

Ruth Ladenstein is professor of Pediatrics at the Children's Cancer Research Institute Vienna (CCRI).
> more

 

Holger Lode, MD

Holger Lode is professor and Chair of the Department of General Pediatrics and Pediatric Hematology and Oncology at the University Medicine Greifswald.
> more

 

Friedrich Lottspeich, MD PhD

Head of Protein Analysis, Max Planck Institute for Biochemistry, Martinsried. He is one of the leading international experts in the area of proteomics, more than 650 scientific publications.
> more

 

Marc Salzberg, MD

Marc Salzberg has vast experience in clinical research both in the academic and commercial field. He worked in numerous clinical research and senior management positions.
> more

 

Hellmut Samonigg, MD

Specialist in internal medicine and hemato-oncology, Rector of Medicinal University Graz
> more

 

Wolfgang Stoiber, MD

Wolfgang Stoiber has over 25 years experience as a physician, pharmaceutical industry executive and as an investment banker.
> more